ReviewEFORT open reviews2019
Molecular understanding of pharmacological treatment of osteoporosis.
Review in EFORT open reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Trial
- First-line treatment of osteoporosis with osteoanabolic therapy: a new opportunity.Internal medicine journal · 2025Review
- Stem Cell and Regenerative Therapies for the Treatment of Osteoporotic Vertebral Compression Fractures.International journal of molecular sciences · 2024Review
- New Horizons in the Treatment of Age-Associated Obesity, Sarcopenia and Osteoporosis.Drugs & aging · 2022Article
- Elevation of transaminases associated with teriparatide treatment: a case report.European journal of hospital pharmacy : science and practice · 2022Review
- Sclerostin: from bench to bedside.Journal of bone and mineral metabolism · 2021Review
- Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases.RSC medicinal chemistry · 2021Review
- The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study.BMC musculoskeletal disorders · 2020Article
- Investigation of long non-coding RNA expression profiles in patients with post-menopausal osteoporosis by RNA sequencing.Experimental and therapeutic medicine · 2020Article
- The Antiosteoporosis Effects of Yishen Bugu Ye Based on Its Regulation on the Differentiation of Osteoblast and Osteoclast.BioMed research international · 2020Article
- Preventive Effects ofEvidence-based complementary and alternative medicine : eCAM · 2020Article
- Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis.Journal of mid-life healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a serious health concern, particularly in aged societies. The burden of osteoporosis with its associated morbidity and mortality due to fracture has become a critical socioeconomic problem.Skeletal integrity is maintained through a balance of bone resorption and bone formation. The bone turnover process, called bone remodelling.Recently, a number of anti-osteoporosis drugs with excellent anti-osteoporosis and fracture effects have been developed. They are mainly classified into two groups according to their effects on bone remodelling: anti-resorptive agents and anabolic agents. Cite this article:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.